Diabetic Neuropathy. Friedrich A. Gries

Widder RA, Brunner R, Walter P, Lüke C, Bartz-Schmidt KU, Heimann K, Borberg H. Improvement of visual acuity in patients suffering from diabetic retinopathy after membrane differential filtration: a pilot study. Transfus Sci 1999; 21: 201-6.

[176] Krolewski M, Eggers P, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35-year follow-up study. Kidney Int 1996; 50: 2041-6.

[177] Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-94.

      [178] Ballard DJ, Humphrey LL, Melton LJ, Frohnert PP, Chu C-P. O'Fallon WM, Palumbo PJ. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minn. Diabetes 1988; 37: 405-12.

[179] Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon M, Palumbo PJ. Chronic renal failure in non-insulin dependent diabetes mellitus. A population based study in Rochester. Minn. Ann Intern Med 1989; 111: 788-96.

[180] Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-5.

[181] Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-98.

[182] Haffner SM. Is there a glycemic threshold? Arch Intern Med 1997; 157: 1791.

[183] Borch-Johnsen K, Kreiner S. Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651-4.

[184] Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987; 30: 144-8.

[185] Moloney A, Turnbridge WMG, Ireland JT, Watkins PJ. Mortality from diabetic nephropathy in the United Kingdom. Diabetologia 1983; 25: 26-30.

[186] Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 29: 230-3.

[187] Matthiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-6.

[188] Brunner FP, Selwood NH. Profile of patient on RRT in Europe and death rate due to major causes of death groups. The EDTA Registration Committee. Kidney Int 1992; 38 (suppl): S4-15.

[189] Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/ creatinine ratio. J Am Soc Nephrol 1996; 7: 930-7.

[190] Ravid M, Savin H, Jutin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994; 45 (suppl): S161-164.

[191] Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.

[192] Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-5.

[193] Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH. Is diabetic nephropathy an inherited complication ? Kidney Int 1992; 41: 719-22.

[194] Toeller M, Buyken A, Heitkamp G, Brämswig S, Man J, Milne R, Gries FA, Keen H, and the EURODIAB IDDM Complications Study Group. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997; 40: 1219-26.

[195] Mogensen CE. Natural history of renal functional abnormalities in human diabetes mellitus: from normoalbuminuria to incipient and overt nephropathy. In: Brenner BM, Stein JH, editors. The kidney in diabetes mellitus. New York: Churchill Livingstone; 1989: 19-49.

[196] Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38: 1077-81.

      [197] Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences and prevention. Diabetologia 1992; 35: 803-12.

[198] Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients, Diabetologia 1993; 36: 1064-70.

[199] Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306-9.

      [200] Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuria type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1051-6.

      [201] Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartman A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-90.

[202] Sawicki PT. Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Diabetes Treatment and Teaching Programmes Working Group. Nephrol Dial Transplant 1997; 12: 1890-9.

[203] European Diabetes Policy Croup. A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999; 16: 716-30.

[204] American Diabetes Association. Diabetic nephropathy. Diabetes Care 2000; 23 (suppl 1): S67-72.

[205] EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.

[206] UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes, UKPDS 39. BMJ 1998; 317: 713-20.

      [207] Marre MJ, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-5.

      [208] Microalbuminuria Captopril Study Group. Captopril reduced the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-93.

      [209] Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, Nakayama M, Hara T, Matsuo S, Sakamoto N. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med 1996; 13: 120-4.

      [210] Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-81.

      [211] Jungmann E, Haak T, Malanyn M, Mortasawi N, Unterstöger E, Scherberich J, Usadel KH: Vergleichsstudie zur Wirkung von Nitrendipin und Enalapril auf Mikroalbuminuria und Alpha-1-Mikroglobulin-Ausscheidung bei Patienten mit Typ 1 Diabetes mellitus. Diabetes Stoffw 1993; 2: 372-7.

[212] Crepaldi G, Casta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa MG, Nosadini R. The Italian Microalbuminuria Study Group in IDDM: Effect of lisinopril and nifedepine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104-10.

[213] Bjorck S, Mulec H, Johnson SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43.

      [214] Lewis EJ, Hunsicker LG, Bani RP, Rhode RD. The effect of angiotensin-converting-enzyme inhibition